Abstract | IMPORTANCE OF THE FIELD: AREAS COVERED IN THIS REVIEW: This article summarizes tagatose Phase I and II diabetes trials. It describes the pharmacodynamics and possible mechanism of action of this agent. Literature from 1974 to 2009 is reviewed. WHAT THE READER WILL GAIN: TAKE HOME MESSAGE:
|
Authors | Ikna Espinosa, Leon Fogelfeld |
Journal | Expert opinion on investigational drugs
(Expert Opin Investig Drugs)
Vol. 19
Issue 2
Pg. 285-94
(Feb 2010)
ISSN: 1744-7658 [Electronic] England |
PMID | 20050825
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Hexoses
- Hypoglycemic Agents
- Sweetening Agents
- tagatose
|
Topics |
- Animals
- Diabetes Mellitus, Type 2
(drug therapy)
- Drug Evaluation
- Glycogenolysis
(drug effects)
- Hexoses
(chemistry, pharmacokinetics, pharmacology, therapeutic use)
- Humans
- Hyperglycemia
(drug therapy)
- Hypoglycemic Agents
(chemistry, pharmacokinetics, pharmacology, therapeutic use)
- Liver
(drug effects)
- Sweetening Agents
(therapeutic use)
|